The Analysis Study of Effects of Oral Antidiabetic Drugs on Tuberculosis Risk and Treatment Outcomes : A Comprehensive Systematic Review
Keywords:
Diabetes mellitus, tuberculosis, metformin, OADAbstract
Background: Diabetes mellitus triples the risk of infection, leading to poor clinical outcomes. Hyperglycemia suppresses immune responses, affecting TB and diabetes patients. Modulation of host cell responses and targeting pathogens could improve treatment outcomes and reduce drug resistance. Methods: Following PRISMA 2020 guidelines, this systematic review focused exclusively on full-text articles published in English between 2014 and 2024. Result: The study conducted a comprehensive review of over 600 publications sourced from reputable databases, including ScienceDirect, SagePub, and PubMed. Following an initial screening, eight publications were identified as warranting more in-depth analysis. Consequently, a thorough review of these selected studies was performed to ensure a detailed and rigorous evaluation. Conclusion: Metformin, an oral antidiabetic (OAD) agent, is associated with reduced incidence and mortality from active tuberculosis in patients with diabetes. In contrast, saxagliptin, another oral antidiabetic drug, is linked to an increased risk of active tuberculosis. The continuing examination of the association between metformin and tuberculosis risk highlights the need for further research to better elucidate and validate these associations.
References
Yew WW, Chang KC, Chan DP, Zhang Y. Metformin as a host-directed therapeutic in tuberculosis: Is there a promise? Tuberculosis (Edinb). 2019 Mar;115:76-80. doi: 10.1016/j.tube.2019.02.004. Epub 2019 Feb 13. PMID: 30948180.
Ryndak MB, Laal S. Mycobacterium tuberculosis Primary Infection and Dissemination: A Critical Role for Alveolar Epithelial Cells. Front Cell Infect Microbiol. 2019 Aug 21;9:299. doi: 10.3389/fcimb.2019.00299. PMID: 31497538; PMCID: PMC6712944.
Sutter A, Landis D, Nugent K. The potential role for metformin in the prevention and treatment of tuberculosis. J Thorac Dis. 2022 Jun;14(6):1758-1765. doi: 10.21037/jtd-22-39. PMID: 35813707; PMCID: PMC9264069.
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008 Jul 15;5(7):e152. doi: 10.1371/journal.pmed.0050152. PMID: 18630984; PMCID: PMC2459204.
Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis (Edinb). 2013 Dec;93 Suppl(0):S10-4. doi: 10.1016/S1472-9792(13)70004-0. PMID: 24388642; PMCID: PMC4019931.
Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol. 2015 Apr;15(4):255-63. doi: 10.1038/nri3813. Epub 2015 Mar 13. PMID: 25765201.
Padmapriydarsini C, Mamulwar M, Mohan A, Shanmugam P, Gomathy NS, Mane A, Singh UB, Pavankumar N, Kadam A, Kumar H, Suresh C, Reddy D, Devi P, Ramesh PM, Sekar L, Jawahar S, Shandil RK, Singh M, Menon J, Guleria R. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis. Clin Infect Dis. 2022 Aug 31;75(3):425-434. doi: 10.1093/cid/ciab964. PMID: 34849651; PMCID: PMC9427151.
Yu X, Li L, Xia L, Feng X, Chen F, Cao S, Wei X. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. BMC Infect Dis. 2019 Oct 17;19(1):859. doi: 10.1186/s12879-019-4548-4. PMID: 31623569; PMCID: PMC6796338.
Zhang M, He JQ. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020 Feb;76(2):149-159. doi: 10.1007/s00228-019-02786-y. Epub 2019 Nov 30. PMID: 31786617.
Heo E, Kim E, Jang EJ, Lee CH. The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus. BMC Pulm Med. 2021 Sep 25;21(1):303. doi: 10.1186/s12890-021-01667-4. PMID: 34563159; PMCID: PMC8464151.
Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ, Duggirala R, Morales-Romero J, López-Alvarenga JC, Comas I, Zenteno-Cuevas R. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis (Edinb). 2017 Mar;103:83-91. doi: 10.1016/j.tube.2017.01.006. Epub 2017 Jan 24. PMID: 28237037.
Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One. 2017 Apr 21;12(4):e0175925. doi: 10.1371/journal.pone.0175925. PMID: 28430796; PMCID: PMC5400500.
Yu X, Li L, Xia L, Feng X, Chen F, Cao S, Wei X. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. BMC Infect Dis. 2019 Oct 17;19(1):859. doi: 10.1186/s12879-019-4548-4. PMID: 31623569; PMCID: PMC6796338.
Meregildo-Rodriguez ED, Asmat-Rubio MG, Zavaleta-Alaya P, Vásquez-Tirado GA. Effect of Oral Antidiabetic Drugs on Tuberculosis Risk and Treatment Outcomes: Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2022 Oct 31;7(11):343. doi: 10.3390/tropicalmed7110343. PMID: 36355885; PMCID: PMC9694577.
Mishra, R., Krishan, S., Rai, P. K., Kapur, P., Khayyam, K. U., Azharuddin, M., Sharma, K., & Sharma, M. (2022). Effect and possible mechanisms of metformin as adjuvant therapy in the management of tuberculosis: A prospective study. Clinical Epidemiology and Global Health, 16. https://doi.org/10.1016/j.cegh.2022.101106
Vyas, N., Punchathidil, R., Swain, A., Shakeer, I., Reddy, B. S., Manu, M. K., & Miraj, S. S. (2022). Repurposing of Metformin for the prevention and treatment of Tuberculosis. Brazilian Journal of Pharmaceutical Sciences, 58. https://doi.org/10.1590/s2175-97902022e20422
Al-Bari MAA, Peake N, Eid N. Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges. World J Diabetes. 2024 May 15;15(5):853-866. doi: 10.4239/wjd.v15.i5.853. PMID: 38766427; PMCID: PMC11099355.
Zhang M, He JQ. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020 Feb;76(2):149-159. doi: 10.1007/s00228-019-02786-y. Epub 2019 Nov 30. PMID: 31786617.
Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013:828939. doi: 10.1155/2013/828939. Epub 2013 Feb 12. PMID: 23476764; PMCID: PMC3583136.
Meregildo-Rodriguez ED, Chunga-Chévez EV, Gianmarco RL, Vásquez-Tirado GA. Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis. Infez Med. 2022 Jun 1;30(2):194-203. doi: 10.53854/liim-3002-4. PMID: 35693063; PMCID: PMC9177183.
Duan H, Liu T, Zhang X, Yu A, Cao Y. Statin use and risk of tuberculosis: a systemic review of observational studies. Int J Infect Dis. 2020 Apr;93:168-174. doi: 10.1016/j.ijid.2020.01.036. Epub 2020 Jan 23. PMID: 31982626.
Li X, Sheng L, Lou L. Statin Use May Be Associated With Reduced Active Tuberculosis Infection: A Meta-Analysis of Observational Studies. Front Med (Lausanne). 2020 Apr 24;7:121. doi: 10.3389/fmed.2020.00121. PMID: 32391364; PMCID: PMC7194006.
Lin SY, Tu HP, Lu PL, Chen TC, Wang WH, Chong IW, Chen YH. Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. Respirology. 2018 Nov;23(11):1063-1073. doi: 10.1111/resp.13338. Epub 2018 Jun 25. PMID: 29943489.
Tseng CH. Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients. J Clin Med. 2018 Sep 9;7(9):264. doi: 10.3390/jcm7090264. PMID: 30205606; PMCID: PMC6162822.
Fu CP, Lee CL, Li YH, Lin SY. Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital. J Diabetes Investig. 2021 Sep;12(9):1603-1609. doi: 10.1111/jdi.13523. Epub 2021 Mar 3. PMID: 33550691; PMCID: PMC8409838.
Saxagliptin and tuberculosis. Prescrire Int. 2013 Jan;22(134):17. PMID: 23383408.
Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions. Prescrire Int. 2011 Feb;20(113):33-7. PMID: 21488586.
Downloads
Published
Versions
- 2024-06-03 (2)
- 2024-09-03 (1)
Issue
Section
License
Copyright (c) 2024 Rachmad Alsy Setiafadi, Nor Anisatun Nida, Muhammad Naufal Marom (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
